Previous 10 | Next 10 |
Pulmatrix ( NASDAQ: PULM ) on Tuesday said it had dosed the first five subjects in its phase 1 trial evaluating its acute migraine treatment PUR3100. The early-stage trial has been designed to assess the safety, tolerability and pharmacokinetics of inhaled PUR3100. The...
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine New inhaled formulation of dihydroergotamine (DHE) intended for acute migraine therapy begins clinical development with Phase 1 study PR Newswire LEXINGTON, Mass. , Jul...
Pulmatrix press release (NASDAQ:PULM): Q1 GAAP EPS of -$1.51 misses by $0.10. Revenue of $1.16M (-16.5% Y/Y) beats by $0.09M. For further details see: Pulmatrix GAAP EPS of -$1.51 misses by $0.10, revenue of $1.16M beats by $0.09M
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass. , May 12, 2022 /PRNewswire/ -- Pulm...
Pulmatrix press release (NASDAQ:PULM): FY GAAP EPS of -$8.63 misses by $0.83. Revenue of $5.17M (-59.1% Y/Y). For further details see: Pulmatrix GAAP EPS of -$8.63 misses by $0.83, revenue of $5.17M
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update PR Newswire LEXINGTON, Mass. , March 29 , 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative in...
The clinical-stage biopharmaceutical company Pulmatrix (NASDAQ:PULM) has lost ~5% in the pre-market Monday after announcing the topline results from its Phase 1b clinical study for PUR1800 in patients with stable Chronic Obstructive Pulmonary Disease (COPD). PUR1800, an inhalational...
United Time Technology (UTME) +46%. BT Brands (BTBD) +37%. O2Micro International (OIIM) +31%. Anaplan (PLAN) +28% Thoma Bravo agrees to buy Anaplan for $10.7B. Vinco Ventures (BBIG) +22%. Marine Petroleum (MARPS) +21%. Mullen Automotive (MULN) +20%. Cuentas (CUEN) +14% pa...
Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD PR Newswire LEXINGTON, Mass. , March 21, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative i...
Pulmatrix (NASDAQ:PULM) said it regained compliance with the applicable Nasdaq minimum bid price continued listing requirement. PULM had previously been notified by Nasdaq on Aug. 17 that it was not in compliance with the minimum bid price rule. To regain compliance, TRIN was required to main...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...